Company intelligence / Profile preview

BioConscious Technologies

Vancouver, British Columbia, Canadabioconscious.tech ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

BioConscious Technologies has developed Endobits, an AI-driven platform that integrates with continuous glucose monitors and EHRs to provide real-time, predictive insights for diabetes management. The system is live in multiple North American clinics, supports reimbursement under US CPT codes, and leverages GPT-based large language models for clinical recommendations. Clinical studies have demonstrated its effectiveness in forecasting glycemic events up to 60 minutes ahead.

Therapeutic areas: Endocrinology
Modalities: Device (Continuous Glucose Monitoring integration)Software (AI-powered clinical decision support)
Industry: Digital Health Medical Devices

Partnerships

Dexcom (API integration with Dexcom CGM devices)

Beyond the preview

Go deeper on BioConscious Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioConscious Technologies.

Explore the full profile